---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-002988"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2023-03-07T23:59:59+00:00"
generated_at: "2026-06-18T09:48:54.942477+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Voyager reports Q4 2022 net loss of $23.6M; highlights partnerships with Neurocrine, Novartis, Pfizer

## Summary
- Q4 2022 net loss $23.6M vs $5.7M income in Q4 2021; full-year net loss $46.4M vs $71.2M loss in 2021.
- Neurocrine collaboration closed Jan 2023: $175M upfront, up to $4.2B milestones, plus royalties and opt-in for GBA1 program.
- Novartis exercised capsid license options for two CNS targets (March 2023): $25M payment, up to $600M milestones plus royalties.
- Pfizer exercised capsid option in Oct 2022: $10M payment, up to $290M milestones plus royalties.
- Cash $118.8M at Dec 31, 2022; expected into 2025 after deals. Pipeline: VY-TAU01 selected, SOD1 candidate in H1 2023.

## SEC filing metadata
- accession: 0001558370-23-002988
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2023-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000155837023002988/0001558370-23-002988-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000155837023002988/vygr-20230307x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-002988
- JSON: https://secwatch.observer/filing/0001558370-23-002988.json
- Plain text: https://secwatch.observer/filing/0001558370-23-002988.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.